Compare Stocks: IOVA, IBRX, TGTX, and RYTM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.64 +4.4%	$7.66	$1.95 ▼ $12.43	$8.10B	0.03	9.41 million shs	9.38 million shs
IOVA Iovance Biotherapeutics	$6.34 +2.1%	$4.40	$1.76 ▼ $6.92	$2.87B	0.71	20.37 million shs	30.91 million shs
RYTM Rhythm Pharmaceuticals	$115.63 +3.1%	$102.51	$74.50 ▼ $122.20	$7.92B	1.92	700,335 shs	672,761 shs
TGTX TG Therapeutics	$49.76 +0.4%	$51.47	$25.28 ▼ $59.30	$7.62B	1.62	2.35 million shs	1.77 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+6.56%	-13.87%	-10.22%	+221.01%
IOVA Iovance Biotherapeutics	0.00%	+55.77%	+45.08%	+75.14%	+145.74%
RYTM Rhythm Pharmaceuticals	0.00%	+16.50%	+0.13%	+22.79%	+28.46%
TGTX TG Therapeutics	0.00%	-4.36%	-15.75%	+16.10%	+79.64%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IBRX ImmunityBio	$7.64 +4.4%	$7.66	$1.95 ▼ $12.43	$8.10B	0.03	9.41 million shs	9.38 million shs
IOVA Iovance Biotherapeutics	$6.34 +2.1%	$4.40	$1.76 ▼ $6.92	$2.87B	0.71	20.37 million shs	30.91 million shs
RYTM Rhythm Pharmaceuticals	$115.63 +3.1%	$102.51	$74.50 ▼ $122.20	$7.92B	1.92	700,335 shs	672,761 shs
TGTX TG Therapeutics	$49.76 +0.4%	$51.47	$25.28 ▼ $59.30	$7.62B	1.62	2.35 million shs	1.77 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IBRX ImmunityBio	0.00%	+6.56%	-13.87%	-10.22%	+221.01%
IOVA Iovance Biotherapeutics	0.00%	+55.77%	+45.08%	+75.14%	+145.74%
RYTM Rhythm Pharmaceuticals	0.00%	+16.50%	+0.13%	+22.79%	+28.46%
TGTX TG Therapeutics	0.00%	-4.36%	-15.75%	+16.10%	+79.64%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IBRX ImmunityBio	2.71	Moderate Buy	$14.20	85.86% Upside
IOVA Iovance Biotherapeutics	2.30	Hold	$8.00	26.18% Upside
RYTM Rhythm Pharmaceuticals	2.78	Moderate Buy	$142.44	23.18% Upside
TGTX TG Therapeutics	2.44	Hold	$63.00	26.61% Upside

Current Analyst Ratings Breakdown

Latest IOVA, IBRX, TGTX, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$6.00
8/7/2026	IOVA Iovance Biotherapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
8/7/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$11.00 ➝ $13.00
8/7/2026	IOVA Iovance Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Market Outperform	$5.00 ➝ $8.00
8/7/2026	RYTM Rhythm Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$145.00 ➝ $146.00
8/7/2026	TGTX TG Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$65.00 ➝ $72.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$154.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/5/2026	RYTM Rhythm Pharmaceuticals	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$160.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$142.00 ➝ $143.00
8/5/2026	RYTM Rhythm Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$141.00 ➝ $155.00

(Data available from 8/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IBRX ImmunityBio	$113.29M	71.47	N/A	N/A	($0.51) per share	-14.98
IOVA Iovance Biotherapeutics	$263.50M	10.90	N/A	N/A	$1.76 per share	3.60
RYTM Rhythm Pharmaceuticals	$189.76M	41.76	N/A	N/A	$2.08 per share	55.59
TGTX TG Therapeutics	$616.29M	12.36	$2.80 per share	17.76	$4.08 per share	12.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IBRX ImmunityBio	-$351.40M	-$0.97	N/A	N/A	N/A	-598.55%	N/A	-51.65%	N/A
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.92%	-31.66%	N/A
RYTM Rhythm Pharmaceuticals	-$196.54M	-$3.11	N/A	N/A	N/A	-85.59%	-159.87%	-44.00%	N/A
TGTX TG Therapeutics	$447.18M	$2.74	18.16	17.90	1.65	55.22%	73.49%	34.14%	N/A

Latest IOVA, IBRX, TGTX, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$198.63 million
8/4/2026	Q2 2026	IBRX ImmunityBio	-$0.08	-$0.22	-$0.14	-$0.22	$49.70 million	$51.24 million
8/4/2026	Q2 2026	RYTM Rhythm Pharmaceuticals	-$0.8072	-$0.73	+$0.0772	-$0.73	$67.66 million	$71.26 million
8/3/2026	Q2 2026	TGTX TG Therapeutics	$0.3057	$0.05	-$0.2557	$0.05	$229.77 million	$240.34 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IBRX ImmunityBio	N/A	5.72	5.70
IOVA Iovance Biotherapeutics	N/A	3.60	3.15
RYTM Rhythm Pharmaceuticals	N/A	3.45	3.20
TGTX TG Therapeutics	1.23	4.27	3.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IBRX ImmunityBio	8.58%
IOVA Iovance Biotherapeutics	77.03%
RYTM Rhythm Pharmaceuticals	N/A
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
IBRX ImmunityBio	66.10%
IOVA Iovance Biotherapeutics	7.80%
RYTM Rhythm Pharmaceuticals	5.90%
TGTX TG Therapeutics	8.87%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IBRX ImmunityBio	590	1.06 billion	359.28 million	Optionable
IOVA Iovance Biotherapeutics	500	452.97 million	417.64 million	Optionable
RYTM Rhythm Pharmaceuticals	140	68.53 million	64.49 million	Optionable
TGTX TG Therapeutics	290	153.07 million	139.49 million	Optionable

IOVA, IBRX, TGTX, and RYTM Headlines

Recent News About These Companies

TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Consensus Rating of "Hold" from Brokerages

August 8 at 4:13 AM | marketbeat.com

JPMorgan Chase & Co. Issues Positive Forecast for TG Therapeutics (NASDAQ:TGTX) Stock Price

August 7 at 12:59 PM | marketbeat.com

Q4 EPS Estimates for TG Therapeutics Lifted by HC Wainwright

August 7 at 1:28 AM | americanbankingnews.com

California State Teachers Retirement System Increases Stock Position in TG Therapeutics, Inc. $TGTX

August 6 at 3:37 AM | marketbeat.com

Q3 EPS Estimates for TG Therapeutics Cut by HC Wainwright

August 6 at 1:13 AM | americanbankingnews.com

HC Wainwright Expects Higher Earnings for TG Therapeutics

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Shares Purchased by Sei Investments Co.

August 5, 2026 | marketbeat.com

Empowered Funds LLC Increases Stake in TG Therapeutics, Inc. $TGTX

August 5, 2026 | marketbeat.com

TG Therapeutics, Inc. $TGTX Stock Holdings Boosted by Dimensional Fund Advisors LP

August 5, 2026 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Stock Price Down 9% Following Weak Earnings

August 5, 2026 | americanbankingnews.com

TG Therapeutics Q3 EPS Estimate Lowered by HC Wainwright

August 4, 2026 | marketbeat.com

TG Therapeutics : TGTX

August 4, 2026 | 247wallst.com

TG Therapeutics (TGTX) Is Down 15.9% After Q2 Miss But Raised 2026 Outlook - What's Changed

August 4, 2026 | finance.yahoo.com

TG Therapeutics: Why I'm Staying Long After The Q2 Selloff

August 3, 2026 | seekingalpha.com

TG Therapeutics: Q2 Earnings Snapshot

August 3, 2026 | wtop.comW

TG Therapeutics (TGTX) Q2 2026 Earnings

August 3, 2026 | 247wallst.com

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

August 3, 2026 | uk.finance.yahoo.com

Three noteworthy biotechs just reported earnings — and only one recovered

August 3, 2026 | msn.com

TG Therapeutics CEO Says Briumvi Is On Track To Become A $1B US Drug – Retail Shrugs Off EPS Miss

August 3, 2026 | finance.yahoo.com

TG Therapeutics raises 2026 outlook following strong Briumvi sales growth

August 3, 2026 | msn.com

TGTX Q2 Earnings Lag, Sales Rise Y/Y, 2026 View Raised, Stock Down

August 3, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, IBRX, TGTX, and RYTM Company Descriptions

ImmunityBio NASDAQ:IBRX

$7.64 +0.32 (+4.37%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$7.59 -0.05 (-0.68%)

As of 08/7/2026 07:59 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Iovance Biotherapeutics NASDAQ:IOVA

$6.34 +0.13 (+2.09%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$6.34 0.00 (-0.02%)

As of 08/7/2026 07:57 PM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Rhythm Pharmaceuticals NASDAQ:RYTM

$115.63 +3.53 (+3.15%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$117.50 +1.87 (+1.62%)

As of 08/7/2026 07:34 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

TG Therapeutics NASDAQ:TGTX

$49.76 +0.21 (+0.42%)

Closing price 08/7/2026 04:00 PM Eastern

Extended Trading

$49.62 -0.14 (-0.27%)

As of 08/7/2026 07:58 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IOVA, IBRX, TGTX, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IOVA, IBRX, TGTX, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IOVA, IBRX, TGTX, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, IBRX, TGTX, and RYTM Company Descriptions

ImmunityBio NASDAQ:IBRX

Iovance Biotherapeutics NASDAQ:IOVA

Rhythm Pharmaceuticals NASDAQ:RYTM

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IOVA, IBRX, TGTX, and RYTM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IOVA, IBRX, TGTX, and RYTM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IOVA, IBRX, TGTX, and RYTM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, IBRX, TGTX, and RYTM Company Descriptions

ImmunityBio NASDAQ:IBRX

Iovance Biotherapeutics NASDAQ:IOVA

Rhythm Pharmaceuticals NASDAQ:RYTM

TG Therapeutics NASDAQ:TGTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools